Clotrimazole: New Drug for Systemic Mycoses?
Authors: JOHN E. BENNETT
Journal: Annals of Internal Medicine (1970)

Editorial Notes1 October 1970Clotrimazole: New Drug for Systemic Mycoses?JOHN E. BENNETT, M.D., F.A.C.P.JOHN E. BENNETT, M.D., F.A.C.P.Search for more papers by this authorAuthor, Article, and Disclosure Informationhttps://doi.org/10.7326/0003-4819-73-4-653 SectionsAboutPDF ToolsAdd to favoritesDownload CitationsTrack CitationsPermissions ShareFacebookTwitterLinkedInRedditEmail ExcerptEnthusiastic reports from Germany have aroused interest in a new antifungal agent called clotrimazole (Bay 5097). This synthetic organic chemical has inhibited the growth of some bacteria and most pathogenic fungi tested in vitro, including fungi causing ringworm and those causing systemic mycoses (1). Clinical trials with oral therapy of systemic mycoses have produced very little toxicity and very favorable therapeutic responses (2-4). No data for clinical efficacy in ringworm have been published.Now that clinical trials in systemic mycoses will soon begin in the United States, it is worthwhile to analyze the available data critically. At this early stage...References1. PLEMPEL M, BARTMANN K, and BÜCHELL K: Experimental study of a new orally effective broad-spectrum antimycotic agent. German Med Monthly 14:532-537, 1969 MedlineGoogle Scholar2. OBERSTE-LEHN H, BAGGESEN I, and PLEMPEL M: Preliminary clinical studies of a new oral antimycotic agent in systemic mycosis. Ibid., pp. 537-539 Google Scholar3. FRIES A: Bay b 5097, a new orally applicable antifungal substance with broad spectrum activity: preliminary clinical data in adults. Ninth Interscience Conference on Antimicrobial Agents and Chemotherapy, Washington, D.C., 27-29 October 1969 Google Scholar4. MARGET W and ADAM D: Bay b 5097, a new orally applicable antifungal substance with broad spectrum activity. Preliminary clinical and laboratory experiences in pediatrics. Ninth Interscience Conference on Antimicrobial Agents and Chemotherapy, Washington, D.C., 27-29, October 1969 Google Scholar5. ELLIS C and SPIVAK M: The significance of candidemia. Ann Intern Med 67:511-522, 1967 LinkGoogle Scholar This content is PDF only. To continue reading please click on the PDF icon. Author, Article, and Disclosure InformationAuthors: JOHN E. BENNETT, M.D., F.A.C.P.Affiliations: National Institute of Allergy and Infectious Diseases National Institutes of Health Bethesda, Md. PreviousarticleNextarticle Advertisement FiguresReferencesRelatedDetails Metrics Cited byInhibition of steroidogenic cytochrome P-450 enzymes in rat testis by ketoconazole and related imidazole anti-fungal drugsDisposition of ketoconazole, an oral antifungal, in humansKomplikationen und supportive Therapie der Leukämien und malignen Non-Hodgkin-LymphomeNON-BACTERIAL INFECTIONS ASSOCIATED WITH NEOPLASTIC DISEASEChemotherapy of Systemic MycosesLaboratory and clinical experience with clotrimzole (Bay b 5097)Vorläufiger Bericht über die Behandlungsergebnisse mit BAY b 5097 bei Lungenkrankheiten mit Candida im SputumChronic Mucocutaneous Candidiasis: Model-Building in Cellular ImmunityCHARLES H. KIRKPATRICK, M.D., ROBERT R. RICH, M.D., JOHN E. BENNETT, M.D.Infectious Complications of Neoplastic DiseaseChapter 14. Antifungal Agents 1 October 1970Volume 73, Issue 4Page: 653-654KeywordsAntifungalsBacteriaBacterial pathogensClinical trialsDrugsFungal pathogensSystemic mycosesToxicity ePublished: 1 December 2008 Issue Published: 1 October 1970 PDF downloadLoading ...